Overcoming Resistance In Cancer

ORIC is a privately held venture-backed company dedicated to understanding mechanisms of resistance to cancer treatment, and to discovering and developing therapies to overcome resistance in cancer.

The company was founded by doctors Charles Sawyers and Scott Lowe of Memorial Sloan Kettering Cancer Center, who have strong records of discovering innovative cancer targets and treatments. Dr. Sawyers was instrumental in the discovery and development of Gleevec®, Sprycel®, Xtandi® and apalutamide. Dr. Lowe identified BRD4 as a therapeutic target in acute myeloid leukemia. Drugs directed against this target are currently undergoing clinical testing. Both Drs. Sawyers and Lowe remain actively involved with ORIC.